Researchers aimed to determine risk factors that can predict the risk of nonsentinel node metastases (NSNM) in this systematic review and meta-analysis.
Publications
The State of Melanoma: Emergent Challenges and Opportunities
Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma.
FDA Grants Orphan Drug Designation to Novel Immunotherapy in Advanced Melanoma
The FDA has granted an Orphan Drug designation to the novel immunotherapy PVSRIPO for the treatment of patients with advanced melanoma of stage IIB-IV, Istari Oncology, Inc., announced in a press release.1
Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
In this single-arm, phase II trial, researchers sought to evaluate the effectiveness of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.